MetaVia Announces Global Patent Protection for Obesity Therapy DA-1726 Through 2041

MetaVia Pharmaceuticals (NASDAQ: MTYA) announced on February 13, 2026, that it has secured a global patent for its obesity and metabolic therapy candidate, DA-1726, covering territory through 2041. The patent provides exclusive rights to the compound worldwide, protecting its mechanism of action and potential indications. The filing strengthens the company's pipeline and positions DA-1726 for potential future development and licensing opportunities. MTYA shares closed at $12.45 on February 13, 2026, up 2.3% on the NASDAQ.